

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Chronic lymphocytic leukemia (CLL)	Protein kinase C $\beta$ (PRKCB)	<i>In vitro</i> and mouse studies suggest inhibiting PRKCB with sotrastaurin could help treat CLL. In primary CLL cells, the PRKCB inhibitor sotrastaurin decreased proliferation compared with no treatment and did not affect B cells from healthy subjects. In a mouse model of CLL, sotrastaurin decreased spleen size and circulating levels of CLL cells compared with vehicle. Next steps include collaborating with Novartis AG to evaluate sotrastaurin in a Phase II trial to treat CLL and mantle cell lymphoma (MCL). Novartis has sotrastaurin (AEB071) in Phase I testing for diffuse B cell lymphoma (DBCL) and other undisclosed cancers.	Unpatented; licensing status undisclosed	El-Gamal, D. <i>et al. Blood</i> ; published online July 7, 2014; doi:10.1182/blood-2014-05-574830 Contact: John C. Byrd, The Ohio State University, Columbus, Ohio e-mail: <a href="mailto:john.byrd@osumc.edu">john.byrd@osumc.edu</a>
<p><b>SciBX 7(31); doi:10.1038/scibx.2014.918</b>  <b>Published online Aug. 14, 2014</b></p>				